Consult Doctor 24*7

latest RNTCP guidelines for diagnosing pulmonary tb


GIVEN BELOW ARE THE OLDER CHANGES, FOR LATEST CHANGES READ 

RNTCP LATEST CHANGES





*The number of specimen required for diagnosis of smear positive pulmonary TB is two,

with one of them being a morning sputum specimen.

*earlier 3 weeks of cough was necessary, now its of only 2 weeks..

*One specimen positive out of the two is enough to declare a patient as smear positive
TB.

*RNTCP Launches Cat IV (DOTS Plus) treatment for Multi-Drug

* Cat V is for XDR-TB.

*Switched to Category V treatment: A Category IV patient who during treatment is identified as an
“XDR-TB suspect” and who is found to have XDR-TB on testing by an NRL, who subsequently has had
their Category IV treatment stopped and RNTCP Category V treatment initiated.
Definition:-

Multi-drug resistant tuberculosis (MDR-TB) is defined as an isolate of M. tuberculosis resistant to at least isoniazid and rifampicin.
with or without other 
anti-tubercular drugs based on DST results from an RNTCP accredited Culture & DST Laboratory.
All patients that are identified with MDR-TB and are to be treated with an RNTCP Category IV regimen,

Extensively drug-resistant tuberculosis (XDR-TB) is TB showing resistance to at least rifampicin, isoniazid, and any fluoroquinolone, and to at least 1of the 3 following injectable drugs used in anti-TB treatment: capreomycin, kanamycin and amikacin  

• Mono-resistance: A patient whose TB is due to tubercle bacilli that are resistant in vitro to exactly one
anti-TB drug in an RNTCP accredited laboratory.

• Poly-resistance: A patient whose TB is due to tubercle bacilli that are resistant in-vitro to more than
one anti-TB drug, except not both isoniazid and rifampicin in an RNTCP accredited laboratory.

·         *   Drug-resistant case: A patient whose TB is due to tubercle bacilli that are resistant in vitro to at least to  one anti-TB drug according to accepted laboratory methods in an RNTCP accredited laboratory.
*its available in downloadable format .

Category: